| pubmed-article:6100648 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6100648 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:6100648 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:6100648 | lifeskim:mentions | umls-concept:C1254373 | lld:lifeskim |
| pubmed-article:6100648 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:6100648 | pubmed:dateCreated | 1986-3-24 | lld:pubmed |
| pubmed-article:6100648 | pubmed:abstractText | A retrovirus belonging to the family of human T-cell leukemia/lymphoma virus (HTLV) was isolated from several patients with acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC) and asymptomatic homosexual males at increased risk of developing AIDS. This new virus was designated HTLV-III. A serological screening procedure incorporating an enzyme-linked immunosorbent assay (ELISA) and a radioimmunoassay using a Western blot technique was developed employing disrupted HTLV-III as the antigen source. These assays identified serum antibodies to HTLV-III antigens in almost all patients with AIDS, greater than 90% patients with ARC and about 40% of homosexual males at risk for developing AIDS. In a study of transfusion associated AIDS (TA-AIDS) all 19 of the TA-AIDS cases had antibodies to HTLV-III. Similarly 31 of 35 high risk donors who donated to cases of TA-AIDS had antibodies to HTLV-III. All four of the antibody negative high risk donors donated to cases that received blood from at least one other high risk donor. In contrast only 2 of 255 other donors were antibody positive. The data clearly indicate that TA-AIDS cases developed the disease as a result of transmission of HTLV-III through contaminated blood and that HTLV-III is the primary etiologic agent of AIDS. | lld:pubmed |
| pubmed-article:6100648 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6100648 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6100648 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6100648 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6100648 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6100648 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6100648 | pubmed:author | pubmed-author:GalloR CRC | lld:pubmed |
| pubmed-article:6100648 | pubmed:author | pubmed-author:SarngadharanM... | lld:pubmed |
| pubmed-article:6100648 | pubmed:author | pubmed-author:BruceAA | lld:pubmed |
| pubmed-article:6100648 | pubmed:author | pubmed-author:SchüpbachJJ | lld:pubmed |
| pubmed-article:6100648 | pubmed:author | pubmed-author:DeVicoA LAL | lld:pubmed |
| pubmed-article:6100648 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:6100648 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6100648 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6100648 | pubmed:pagination | 301-8 | lld:pubmed |
| pubmed-article:6100648 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:meshHeading | pubmed-meshheading:6100648-... | lld:pubmed |
| pubmed-article:6100648 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6100648 | pubmed:articleTitle | HTLV-III: the etiologic agent of AIDS. | lld:pubmed |
| pubmed-article:6100648 | pubmed:publicationType | Journal Article | lld:pubmed |
